Blocking the activity of interleukin-1 in mouse models of complex regional pain syndrome (CRPS) helped reverse symptoms. Researchers say patients with CRPS should respond to immune-based treatments which reduce some of the disease features.
Researchers report a potential new drug may reduce the number of brain cells destroyed by stoke and also help repair them.
